Please assess the completion status of the following clinical trial:

Trial Title: Basiliximab Maintenance in Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Previously met eligibility criteria in the previous basiliximab UC study~2. Must have a total Mayo score at entry consistent with clinical response or clinical remission.~3. Signed a current IRB/IEC-approved informed consent form~4. Females of childbearing potential must use an effective birth control method, and be willing to continue birth control during the study, and for 4 months after the last dose of study drug.~5. Females of non-childbearing potential should be surgically sterile (bilateral tubal ligation with surgery at least 6 months before study entry, hysterectomy, or bilateral oophorectomy at least 2 months before study entry) or post-menopausal for at least 2 years.~Exclusion Criteria:~1. Subject is severely ill, as evidenced by more than 6 episodes of loose stools, all of them bloody, during a 24-hour period within the prior 7 days, concurrent with any of the following systemic features:~   * Heart rate \> 90 beats/min at rest~  * Temperature \> 37.8 degrees C~  * Hemoglobin \< 10.5 g/dL~2. Subject is currently receiving a restricted/prohibited concomitant medication~3. Subject has undergone colectomy (total, or subtotal)~4. Subject is pregnant or breast-feeding~5. Prior noncompliance with previous study visit schedule and requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).